Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,183
  • Shares Outstanding, K 60,449
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,220 K
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.67
Trade SLDB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.31
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +58.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.00 +2.67%
on 11/10/20
3.76 -18.09%
on 10/26/20
-0.72 (-18.84%)
since 10/23/20
3-Month
1.93 +59.59%
on 09/24/20
6.10 -49.51%
on 10/01/20
+0.74 (+31.62%)
since 08/24/20
52-Week
1.93 +59.59%
on 09/24/20
6.10 -49.51%
on 10/01/20
-1.22 (-28.37%)
since 11/22/19

Most Recent Stories

More News
Solid Biosciences (SLDB) Reports Wider-Than Expected Q3 Loss

Solid Biosciences??? (SLDB) reports wider than expected loss in the third quarter of 2020.

SLDB : 3.08 (-2.22%)
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update

-IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021-

SLDB : 3.08 (-2.22%)
Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release third quarter 2020...

SLDB : 3.08 (-2.22%)
Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?

Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.

ALKS : 18.37 (+0.77%)
ALNY : 125.66 (+2.15%)
RARE : 118.88 (+3.65%)
SLDB : 3.08 (-2.22%)
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy

-Collaboration combines Solid's differentiated microdystrophin construct and Ultragenyx's HeLa PCL manufacturing platform for use with AAV8 and variants-

RARE : 118.88 (+3.65%)
SLDB : 3.08 (-2.22%)
Do Options Traders Know Something About Solid Biosciences (SLDB) Stock We Don't?

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

SLDB : 3.08 (-2.22%)
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial...

SLDB : 3.08 (-2.22%)
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

- Modifications to IGNITE DMD trial protocol and improvements to manufacturing processes enable continued program development -

SLDB : 3.08 (-2.22%)
Sarepta's Casimersen NDA Gets Priority Review From FDA

Sarepta (SRPT) is seeking accelerated approval for exon 45 amenable DMD candidate, casimersen. Amondys 45 is likely to be the brand name for the candidate.

RHHBY : 40.9800 (-0.59%)
PFE : 36.60 (+0.22%)
SRPT : 135.11 (+0.46%)
SLDB : 3.08 (-2.22%)
Sarepta Inks Agreement With Codiak to Develop Gene Therapies

Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.

RHHBY : 40.9800 (-0.59%)
PFE : 36.60 (+0.22%)
SRPT : 135.11 (+0.46%)
SLDB : 3.08 (-2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

2nd Resistance Point 3.32
1st Resistance Point 3.20
Last Price 3.08
1st Support Level 3.01
2nd Support Level 2.94

See More

52-Week High 6.10
Fibonacci 61.8% 4.51
Fibonacci 50% 4.01
Fibonacci 38.2% 3.52
Last Price 3.08
52-Week Low 1.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar